ReviewBioMed research international2014
Update in pathogenesis and prospective in treatment of necrotizing enterocolitis.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06904872 (A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of Adult Patients With Short Bowel Syndrome and Intestinal Failure), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
Who cites it
17 citing papers in PubMed.
- Risk Factors Influencing Neurodevelopmental Outcome and Survival in Preterm Infants: A Prospective Cohort Study.Children (Basel, Switzerland) · 2026Article
- Targeted immune response gene expression profiles linked with necrosis and mortality in preterm infants with surgical necrotizing enterocolitis.World journal of pediatric surgery · 2026Article
- Article
- A quality improvement initiative standardizing the antibiotic treatment and feeding practices in patients with medical necrotizing enterocolitis.Journal of perinatology : official journal of the California Perinatal Association · 2024Article
- Early Energy Intake and Amino Acid Profile in Preterm Newborns: A Quasi-Experimental Study.Nutrients · 2023Article
- Oxygen for the Newborn: Friend or Foe?Children (Basel, Switzerland) · 2023Review
- Ameliorating adverse perinatal outcomes with Lactoferrin: An intriguing chemotherapeutic intervention.Bioorganic & medicinal chemistry · 2022Review
- Impact of Total Parenteral Nutrition on Gut Microbiota in Pediatric Population Suffering Intestinal Disorders.Nutrients · 2022Review
- Neonatal Hyperglycemia Related to Parenteral Nutrition Affects Long-Term Neurodevelopment in Preterm Newborn: A Prospective Cohort Study.Nutrients · 2021Article
- Fecal High-Mobility Group Box 1 as a Marker of Early Stage of Necrotizing Enterocolitis in Preterm Neonates.Frontiers in pediatrics · 2021Article
- Developmental 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure of either parent enhances the risk of necrotizing enterocolitis in neonatal mice.Birth defects research · 2020Article
- Gut Microbiota Modulation: Implications for Infection Control and Antimicrobial Stewardship.Advances in therapy · 2020Review
- Peroxisome proliferator-activated receptor-γ agonist pioglitazone reduces the development of necrotizing enterocolitis in a neonatal preterm rat model.Pediatric research · 2017Article
- Prevention of necrotizing enterocolitis with probiotics: a systematic review and meta-analysis.PeerJ · 2016Article
- Benefits of Bifidobacterium breve M-16V Supplementation in Preterm Neonates - A Retrospective Cohort Study.PloS one · 2016Article
- Review
- Necrotizing enterocolitis in newborns: update in pathophysiology and newly emerging therapeutic strategies.Korean journal of pediatrics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necrotizing enterocolitis (NEC) is among the most common and devastating diseases in neonates and, despite the significant advances in neonatal clinical and basic science investigations, its etiology is largely understood, specific treatment strategies are lacking, and morbidity and mortality remain high. Improvements in the understanding of pathogenesis of NEC may have therapeutic consequences. Pharmacologic inhibition of toll-like receptor signaling, the use of novel nutritional strategies, and microflora modulation may represent novel promising approaches to the prevention and treatment of NEC. This review, starting from the recent acquisitions in the pathogenic mechanisms of NEC, focuses on current and possible therapeutic perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.